MedTrace Logo

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

NCT05140863 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2023-02-27

No results posted yet for this study

Summary

Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

HSK16149 20mg BID

HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose

DRUG

HSK16149 40mg BID

HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose

DRUG

Placebo BID

Placebo, orally twice a day, treatment period; 12-weeks fixed dose

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-12-22
Completion
2023-01-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05140863 on ClinicalTrials.gov